Chaparro, MariaBarreiro-de Acosta, ManuelBenitez, Jose ManuelCabriada, Jose LuisCasanova, Maria JoseCeballos, DanielEsteve, MariaFernandez, HipolitoGinard Vicens, DanielGomollon, FernandoLorente, RufoNos, PilarRiestra, SabinoRivero, MontserratRobledo, PilarRodriguez, CristinaSicilia, BeatrizTorrella, EmilioGarre, AnaGarcia-Esquinas, EstherRodríguez-Artalejo, FernandoGisbert, Javier PEpidemIBD study group of GETECCU2024-09-102024-09-102019-05Chaparro M, Barreiro-De Acosta M, Benitez JM, Cabriada JL, Casanova MJ, Ceballos D, et al. EpidemIBD: rationale and design of a large-scale epidemiological study of inflammatory bowel disease in Spain. Ther Adv Gastroenterol. 2019 May;12:1-11.1756-283Xhttp://hdl.handle.net/20.500.13003/9949https://hdl.handle.net/20.500.12105/22806Background: Inflammatory bowel disease (IBD) is associated with a considerable burden to the patient and society. However, current data on IBD incidence and burden are limited because of the paucity of nationwide epidemiological studies, heterogeneous designs, and a low number of participating centers and sample size. The EpidemIBD study is a large-scale investigation to provide an accurate assessment of the incidence of IBD in Spain, as well as treatment patterns and outcomes. Methods: This multicenter, population-based incidence cohort study included patients aged >18 years with IBD (Crohn's disease, ulcerative colitis, or unclassified IBD) diagnosed during 2017 in 108 hospitals in Spain, covering 50% of the Spanish population. Each participating patient will attend 10 clinic visits during 5 years of follow up. Demographic data, IBD characteristics and family history, complications, treatments, surgeries, and hospital admissions will be recorded. Results: The EpidemIBD study is the first large-scale nationwide study to investigate the incidence of IBD in Spain. Enrollment is now completed and 3627 patients are currently being followed up. Conclusions: The study has been designed to overcome many of the limitations of previous European studies into IBD incidence by prospectively recruiting a large number of patients from all regions of Spain. In addition to epidemiological information about the burden of IBD, the 5-year follow-up period will also provide information on treatment patterns, and the natural history and financial burden of IBD.enghttp://creativecommons.org/licenses/by-nc/4.0/EpidemiologyInflammatory bowel diseaseCrohn's diseaseUlcerative colitisIncidenceresearch articleAttribution-NonCommercial 4.0 International312054851210.1177/17562848198470341756-2848Therapeutic Advances in Gastroenterologyopen access2-s2.0-85066879289478873800001L627801194